[Ning Yihua of Jingyu Medical: China’s brain-computer interface DBS has moved from ecological rise to psychiatric breakthrough] October 14th, at the 22nd ICOCS (International Obsessive-Compulsive and Obsessive-Compulsive Spectrum Disorders Society) Annual Meeting held today, Ning Yihua said that brain-computer interface dual-target DBS is the last resort for refractory mental illness. Chinese companies and clinicians have made milestone breakthroughs in the field of treatment of refractory mental illness. A global "first" has been achieved - the brain-computer interface dual-target DBS for opioid addiction has been approved for marketing in China. Jingyu Medical launched two clinical trials of brain-computer interface dual-target DBS in the treatment of refractory obsessive-compulsive disorder in 2016 and 2021. The 6-month complete response rates were both above 75%. Note: Jingyu Medical is an enterprise in the field of brain-computer interfaces for the treatment of addiction and mental diseases. In December 2025, the company's Neurestora® was approved by the China Food and Drug Administration for marketing. It is used for relapse prevention and auxiliary treatment of patients with refractory moderate to severe opioid addiction, becoming the world's first brain-computer interface dual-target DBS system approved for the treatment of drug addiction.